

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 15 January 2002 (15.01.02)	
International application No. PCT/CA01/00679	Applicant's or agent's file reference 29312-0138
International filing date (day/month/year) 11 May 2001 (11.05.01)	Priority date (day/month/year) 11 May 2000 (11.05.00)
Applicant SAUDER, Daniel et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
 11 December 2001 (11.12.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Paulette BOCCARD (Fax 338.87.40) Telephone No.: (41-22) 338.83.38
---	--

PATENT COOPERATION TREATY

PCT

NOTIFICATION THAT DEMAND OR
ELECTION IS CONSIDERED NOT TO HAVE
BEEN SUBMITTED OR MADE

(PCT Rule 60.1(c) or 60.2(c) and
Administrative Instructions, Section 418)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark Office,
PCT
2011 South Clark Place Room CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 21 February 2002 (21.02.02)	International filing date (day/month/year) 11 May 2001 (11.05.01)
International application No. PCT/CA01/00679	
Applicant VASOGEN IRELAND LIMITED	

1. ☒ The International Bureau hereby notifies the elected Office that the International Preliminary Examining Authority has declared that the demand relating to the international application has been considered as if it had not been submitted.
2. ☐ The International Bureau hereby notifies the elected Office that it has declared that the notice containing the later election of the (following) State(s) for which the Office acts as elected Office has been considered as if it had not been submitted:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Idhir BRITEL (Fax 338.87.40)
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38

PCT REQUEST

29312-0138

Original (for SUBMISSION) - printed on 11.05.2001 10:25:57 AM

0	For receiving Office use only	
0-1	International Application No.	
0-2	International Filing Date	
0-3	Name of receiving Office and "PCT International Application"	
0-4	Form - PCT/RO/101 PCT Request	
0-4-1	Prepared using	PCT-EASY Version 2.91 (updated 01.01.2001)
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	Canadian Patent Office (RO/CA)
0-7	Applicant's or agent's file reference	29312-0138
I	Title of invention	TREATMENT OF IL-10 DEFICIENCIES
II	Applicant	
II-1	This person is:	applicant only
II-2	Applicant for	all designated States except US
II-4	Name	VASOGEN IRELAND LIMITED
II-5	Address:	Shannon Airport House Shannon, Co. Clare Ireland
II-6	State of nationality	IE
II-7	State of residence	IE
II-8	Telephone No.	011 353 6147-2845
II-9	Facsimile No.	011 353 6147 2060
III-1	Applicant and/or inventor	
III-1-1	This person is:	applicant and inventor
III-1-2	Applicant for	US only
III-1-4	Name (LAST, First)	SAUDER, Daniel
III-1-5	Address:	90 Munro Boulevard Toronto, Ontario M2P 1L4 Canada
III-1-6	State of nationality	CA
III-1-7	State of residence	CA

PCT REQUEST

29312-0138

Original (for SUBMISSION) - printed on 11.05.2001 10:25:57 AM

III-2	Applicant and/or inventor	
III-2-1	This person is:	applicant and inventor
III-2-2	Applicant for	US only
III-2-4	Name (LAST, First)	MANDEL, Arkady
III-2-5	Address:	277 Hidden Trail North York, Ontario M2R 3S7 Canada
III-2-6	State of nationality	CA
III-2-7	State of residence	CA
III-3	Applicant and/or inventor	
III-3-1	This person is:	applicant and inventor
III-3-2	Applicant for	US only
III-3-4	Name (LAST, First)	BOLTON, Anthony, E.
III-3-5	Address:	Ivy Cottage Sherwood Road Tideswell, Derbyshire SK17 8HS United Kingdom
III-3-6	State of nationality	GB
III-3-7	State of residence	GB
IV-1	Agent or common representative; or address for correspondence The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent
IV-1-1	Name (LAST, First)	HIRONS, Robert, G.
IV-1-2	Address:	Ridout & Maybee LLP 150 Metcalfe Street 19th Floor Ottawa, Ontario K2P 1P1 Canada
IV-1-3	Telephone No.	613-566-2079
IV-1-4	Facsimile No.	613-236-2485
IV-1-5	e-mail	rhiron@ridoutmaybee.com

PCT REQUEST

3/4

29312-0138

Original (for SUBMISSION) - printed on 11.05.2001 10:25:57 AM

V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<p>AP: GH GM KE LS MW MZ SD SL SZ TZ UG ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT</p> <p>EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT</p> <p>EP: AT BE CH&LI CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR and any other State which is a Contracting State of the European Patent Convention and of the PCT</p> <p>OA: BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT</p>
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<p>AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH&LI CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW</p>
V-5	Precautionary Designation Statement In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.	
V-6	Exclusion(s) from precautionary designations	NONE
VI-1	Priority claim of earlier national application	
VI-1-1	Filing date	11 May 2000 (11.05.2000)
VI-1-2	Number	2,308,105
VI-1-3	Country	CA
VI-2	Priority document request The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as item(s):	VI-1

PCT REQUEST

29312-0138

Original (for SUBMISSION) - printed on 11.05.2001 10:25:57 AM

VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)	
VIII	Check list	number of sheets	electronic file(s) attached
VIII-1	Request	4	-
VIII-2	Description	19	-
VIII-3	Claims	8	-
VIII-4	Abstract	1	EZABST00.TXT
VIII-5	Drawings	5	-
VIII-7	TOTAL	37	
	Accompanying items	paper document(s) attached	electronic file(s) attached
VIII-8	Fee calculation sheet	✓	-
VIII-16	PCT-EASY diskette	-	diskette
VIII-18	Figure of the drawings which should accompany the abstract	1	
VIII-19	Language of filing of the international application	English	
IX-1	Signature of applicant or agent		
IX-1-1	Name (LAST, First)	HIRONS, Robert, G.	

FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	
10-2	Drawings:	
10-2-1	Received	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	

FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	
------	--	--

PCT (ANNEX - FEE CALCULATION SHEET)

29312-0138

Original (for SUBMISSION) - printed on 11.05.2001 10:25:57 AM

(This sheet is not part of and does not count as a sheet of the international application)

0	For receiving Office use only	
0-1	International Application No.	
0-2	Date stamp of the receiving Office	
0-4	Form - PCT/RO/101 (Annex)	
0-4-1	PCT Fee Calculation Sheet Prepared using	PCT-EASY Version 2.91 (updated 01.01.2001)
0-9	Applicant's or agent's file reference	29312-0138
2	Applicant	VASOGEN IRELAND LIMITED, et al.
12	Calculation of prescribed fees	fee amount/multiplier
12-1	Transmittal fee T	⇒ 200
12-2	Search fee S	⇒ 1,320
12-3	International fee	
	Basic fee (first 30 sheets) b1	562
12-4	Remaining sheets	7
12-5	Additional amount (X)	13
12-6	Total additional amount b2	91
12-7	b1 + b2 = B	653
12-8	Designation fees	
	Number of designations contained in international application	87
12-9	Number of designation fees payable (maximum 6)	6
12-10	Amount of designation fee (X)	121
12-11	Total designation fees D	726
12-12	PCT-EASY fee reduction R	-173
12-13	Total International fee (B+D-R) I	⇒ 1,206
12-14	Fee for priority document	
	Number of priority documents requested	1
12-15	Fee per document (X)	0
12-16	Total priority document fee P	⇒ 0
12-17	TOTAL FEES PAYABLE (T+S+I+P)	⇒ 2,726
12-19	Mode of payment	other: VISA
12-20	Deposit account instructions	
	The receiving Office:	Canadian Patent Office (RO/CA)
12-20-2	is hereby authorized to charge any deficiency or credit any over-payment in the total fees indicated above to my deposit account	✓
12-20-3	is hereby authorized to charge the fee for preparation and transmittal of the priority document to the International Bureau of WIPO to my deposit account	✓
12-21	Deposit account No.	600000242

PCT (ANNEX - FEE CALCULATION SHEET)

29312-0138

Original (for SUBMISSION) - printed on 11.05.2001 10:25:57 AM

12-22	Date	11 May 2001 (11.05.2001)
12-23	Name and signature	HIRONS, Robert, G.

VALIDATION LOG AND REMARKS

13-2-6	Validation messages Contents	Yellow! The power of attorney or a copy of the general power of attorney will need to be furnished unless all applicants sign the request form.
--------	---------------------------------	---

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 November 2001 (15.11.2001)

PCT

(10) International Publication Number
WO 01/85185 A2

(51) International Patent Classification⁷: **A61K 35/14**,
41/00, A61P 37/00

(CA). MANDEL, Arkady [CA/CA]; 277 Hidden Trail,
North York, Ontario M2R 3S7 (CA). BOLTON, Anthony,
E. [GB/GB]; Ivy Cottage, Sherwood Road, Tideswell, Der-
byshire SK17 8HS (GB).

(21) International Application Number: PCT/CA01/00679

(22) International Filing Date: 11 May 2001 (11.05.2001)

(74) Agent: HIRONS, Robert, G.; Ridout & Maybee LLP,
150 Metcalfe Street, 19th Floor, Ottawa, Ontario K2P 1P1
(CA).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2,308,105 11 May 2000 (11.05.2000) CA

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): VASO-
GEN IRELAND LIMITED [IE/IE]; Shannon Airport
House, Shannon, Co. Clare (IE).


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SAUDER, Daniel
[CA/CA]; 90 Munro Boulevard, Toronto, Ontario M2P 1L4

[Continued on next page]

(54) Title: TREATMENT OF IL-10 DEFICIENCIES



(57) Abstract: Mammalian disorders associated with a deficiency in the cytokine interleukin-10 (IL-10) can be alleviated by stimulating *in vivo* secretion and/or activity of IL-10 in the patient's blood or tissues by application of external stimulus.



WO 01/85185 A2



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

TREATMENT OF IL-10 DEFICIENCIES

Field of the Invention

This invention relates to the cytokine interleukin-10 (hereafter IL-10), and methods for the treatment or prophylaxis of mammalian disorders associated with IL-10 deficiency.

Background of the Invention and Prior Art

It is known that IL-10, originally described as cytokine synthesis inhibitory factor, plays a role in suppressing immune and inflammatory responses in the mammalian body, by inhibiting the production of pro-inflammatory cytokines. A deficiency of IL-10 results in the development of a number of significant inflammatory events including ischemia-reperfusion injury, and has been implicated in autoimmune diseases such as psoriasis and pemphigus. It has been reported to be a Th2-derived cytokine that inhibits the cytokine release by Th1 cells (see Biorencino et al., J. Exp. Med. 170: 3081-2095, 1989). Studies of the biologic activities of IL-10 *in vitro* have shown that IL-10 inhibits production of cytokines at both mRNA and protein levels by mouse Th1 clones stimulated by antigen or CD3 antibody in the presence of macrophages (see, again, the above cited paper by Biorencino et al.).

Kondo, McKenzie and Sauder, "The Journal of Investigative Dermatology," Vol. 103, 1994, pages 811-814 have reported that IL-10 application suppresses interferon gamma mRNA up-regulation in challenged skin, suggesting that IL-10 significantly modifies the elucidation of allergic contact sensitivity reactions.

The administration of exogenous IL-10 as a therapeutic agent to treat IL-10 deficiency-associated disorders in a mammalian patient, on any significant scale, is currently unattractive. The preparation of IL-10 by chemical

- 2 -

synthesis, or by cell cultivation and expression techniques (e.g., using recombinant DNA technologies) is prohibitively expensive.

Current treatment of pemphigus is with oral steroids, usually prednisone. Immunosuppressive drugs such as Imuran and Cytoxan are also
5 used as adjunctive therapy to the steroid treatment. However, these drugs have serious side effects and, accordingly, treatment for pemphigus which has reduced side effects is needed.

Summary of the Invention

It has now been found that increased secretion of IL-10 can be
10 caused *in vivo*, in a mammalian patient, and that such enhanced secretion of IL-10 *in vivo* has a beneficial, therapeutic effect on a wide variety of mammalian disorders, including, but not limited to inflammatory disorders and disorders arising from a deficient immune system or a deficient endothelial function in the patient.

15 One aspect of the present invention is a method for the prophylactic or therapeutic treatment of inflammatory components and inflammatory aspects of an IL-10 deficiency-mediated disease in a mammalian patient, which method comprises administering to said patient an aliquot of blood which has been treated *ex vivo* with at least one stressor selected from
20 the group consisting of an oxidative environment, thermal stress and UV light, wherein the concentration of IL-10 secreted by immune cells in the blood or tissues of said patient is increased, with an associated reduction of harmful inflammatory effects of the IL-10 deficiency-mediated disease.

In another embodiment, the method comprises (a) identifying a
25 patient having an IL-10 deficiency-mediated disease condition, or is at risk of having an IL-10 deficiency-mediated disease condition, which has a significant inflammatory component; (b) evaluating the patient identified in (a) above to

- 3 -

determine whether that disease condition or risk of disease condition can be effectively treated by increasing the concentration of IL-10 in the patient; and (c) if an increase in the concentration of IL-10 would be suitable for the prophylactic or therapeutic treatment of such a disease, then administering to said patient an
5 aliquot of blood which has been treated *ex vivo* with at least one stressor selected from the group consisting of an oxidative environment, thermal stress and UV light.

Another aspect of the invention is a method for preventing or treating an IL-10 deficiency-associated disorder in a mammalian patient which
10 method comprises (a) identifying a patient having an IL-10 deficiency-mediated disorder which disorder is characterized by a decreased amount of IL-10 secretion; (b) evaluating the patient to determine whether that disorder can be effectively treated by increasing the amount of IL-10 secretion; and (c)
15 administering to the patient an effective amount of extracorporeally stressed blood to stimulate IL-10 secretion in the patient.

Yet another aspect of this invention is a method for preventing or treating an IL-10 deficiency-mediated disorder in a mammalian patient, which method comprises (a) selecting a patient having an IL-10 deficiency-mediated disorder which disorder is characterized by a decreased amount of IL-10
20 secretion; (b) evaluating the patient to determine whether that disorder can be effectively treated by stimulating IL-10 secreting cells; and (c) administering to the patient an effective amount of extracorporeally stressed blood to stimulate IL-10 secreting cells thereby increasing the relative proportion of IL-10 secreting cells in the mammalian patient and stimulating the secretion of IL-10.

25 Another aspect of the invention is a method for preventing or treating an IL-10 deficiency-mediated disorder in a mammalian patient, which method comprises (a) selecting a patient having an IL-10 deficiency-mediated disorder which disorder is characterized by a decreased amount of IL-10 activity; (b) evaluating the patient to determine whether that disorder can be

- 4 -

effectively treated by increasing the activity of IL-10 in the patient; and (c) administering to the patient an effective amount of extracorporeally stressed blood to increase IL-10 activity in the patient.

Another aspect of the invention provides a process of increasing
5 *in vivo* levels of IL-10 in a mammalian patient, by increasing the number or relative proportion of IL-10-secreting cells in the mammalian body or by increasing the amount of IL-10 secretion from IL-10-secreting cells in the mammalian body, or by increasing the activity of IL-10 secreted in the mammalian body, and thereby effecting beneficial therapeutic effects in the
10 patient.

From another aspect, the invention provides biologically acceptable compositions of matter administrable to a mammalian patient, and which, upon or after such administration, stimulate enhanced secretion of IL-10
15 *in vivo* in the mammalian patient, for treatment or prophylaxis of various mammalian disorders.

BRIEF DESCRIPTION OF THE DRAWINGS

The figures of accompanying drawings are graphical presentations of results obtained according to specific examples described below.

20 Figure 1 shows a comparison of ear thickness measurement in mice following treatment as described in Example 1.

Figure 2 is a cross section of the ear of animals treated as described in Example 1.

25 Figure 3 shows a comparison of net ear swelling in mice following treatment as described in Example 2.

- 5 -

Figure 4 shows a comparison of net ear swelling in mice following treatment as described in Example 3.

Figure 5 shows a comparison of net ear swelling in mice following treatment as described in Example 4.

5 DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to methods for the treatment or prophylaxis of mammalian disorders associated with IL-10 deficiency, in particular disease such as pemphigus and psoriasis. The following terms are defined with respect to this application.

10 "Pemphigus" is a group of autoimmune diseases characterized by the formation of watery blisters on the skin. It is an intraepidermal blistering disease characterized clinically by superficial blisters and erosions of the skin and/or mucous membranes, especially the mouth. It is currently treated with massive doses of steroids.

15 It is classified into three major forms: "pemphigus foliaceus," a superficial and more benign form; "pemphigus vulgaris," a deeper, more serious and more common form; and "paraneoplastic pemphigus," the rarest and most serious form which occurs most often in patients who have been diagnosed with a malignancy (cancer).

20 The forms have minor variants. Pemphigus foliaceus ("PF") is caused by the location of the blister just below the stratum corneum of the epidermis. Oral lesions are uncommon. Pemphigus vulgaris ("PV") patients generally present in their fifth to sixth decade, exhibiting blisters and erosions on skin and mucous surfaces. Oral lesions often precede skin lesions by a few
25 months. The lesions appear as erosions due to the fragility of the blisters. The

- 6 -

oral lesions can spread to the pharynx and the larynx, with resulting hoarseness, excruciating pain, and inability to eat and drink. It has a grave prognosis if not treated. Before the introduction of oral steroid treatments, mortality was 100% by 5 years, due to malnutrition, debilitation, sepsis and/or electrolyte and water loss. Paraneoplastic pemphigus patients generally exhibit sores in the mouth, lips and esophagus and skin lesions of different types occur. This form of the disease is usually unresponsive to standard steroid treatment. In some cases, surgical removal of the associated tumor can lead to improvement of the symptoms of pemphigus. Cotell, S.; Robinson, N.D.; and Chan, L.S., American Journal of Emergency Medicine, (May 2000) Vol.18, No.3, page 1, further describe the various types of pemphigus.

Toto, P., Feliciani C, Amerio P, Suzuki H, Wang B, Shivji GM, Woodley D and Sauder DN, *J. Immunol* (1 Jan 2000) 164(1):522-9, report that pemphigus vulgaris ("PV") is characterized by antibodies to the desmosomal cadherin desmoglein-3. This work, on delineating the potential role of T-cell signalling pathways in the pathogenesis of PV, involved passive transfer experiments with PV IgG in gene targeted mutant mice. Data described therein suggests a potential role of IL-10 in PV.

The term "prophylaxis" refers to the prevention of disease or preventive treatment of a disease.

Patients having IL-10 deficiency-associated disorders can be identified by an examination of their symptoms. The presence of the visible symptoms of psoriasis or pemphigus on a patient's skin, or the presence of symptoms of inflammatory bowel disease in a patient, are evidence of IL-10 deficiency. Such identification can also be made, or confirmed, by measurement of IL-10 and IL-10 mRNA in affected tissues of the patient, in the patient's blood and/or the patient's blood cells. IL-10 measurements can be conducted by methods well known to those skilled in the art. See, for example, the aforementioned papers of Biorencino et al. and Kondo et al., page 1 hereof,

- 7 -

and especially references cited therein. Commonly, antibody measurements are used, in plasma or tissue, as with measurements of other cytokines.

A patient thus identified as having an IL-10 deficiency-associated disorder may be evaluated to determine whether that disorder can be effectively
5 treated by increasing the amount of *in vivo* IL-10 secretion, by administering IL-10 from an external source and observing the resultant effect on the patient's symptoms of this disorder. IL-10 is commercially available, at least in test quantities. It can be administered to the test patient intravenously or by local injection at the site of the disorder, as a liquid infusion in a biologically
10 acceptable carrier.

One way to enhance IL-10 secretion is by introduction into the patient of compatible whole blood which has been extracorporeally subjected to an oxidative stress. Another is by introduction into the patient of compatible whole blood which has been subjected extracorporeally to an appropriate dose
15 of UV radiation. Yet another is by introduction into the patient of compatible whole blood which has been subjected extracorporeally to an oxidative stress and an appropriate dose of UV radiation simultaneously.

Still other processes are the introduction into the patient of a cellular fraction of compatible blood, optionally including platelets, which has
20 been subjected extracorporeally to oxidative stress, or one which has been subjected to an appropriate dose of UV radiation extracorporeally, or one which has been subjected extracorporeally to both an oxidative stress and an appropriate dose of UV radiation simultaneously. In all cases it is preferred to use the patient's own blood or blood cells, for extracorporeal processing and
25 introduction into the patient.

A preferred process of the present invention involves extraction of an aliquot of blood from a mammalian subject (preferably a human), and treatment of the aliquot of blood or a separated cellular fraction thereof *ex vivo*,

simultaneously or sequentially, with the oxidative stress and UV radiation. Then it is injected back into the same subject. Preferably a combination of both of the oxidative stressor and the UV radiation is used simultaneously. The result is an enhanced secretion of IL-10 in the mammalian patient.

5 Preferably also, the aliquot of blood is in addition subjected to mechanical stress. Such mechanical stress is suitably that applied to the aliquot of blood by extraction of the blood aliquot through a conventional blood extraction needle, or a substantially equivalent mechanical stress, applied shortly before the other chosen stressors are applied to the blood aliquot. This
10 mechanical stress may be supplemented by the mechanical stress exerted on the blood aliquot by bubbling gases through it, such as ozone/oxygen mixtures, as described below. Optionally also, a temperature stressor may be applied to the blood aliquot, simultaneously or sequentially with the other stressors, i.e., a temperature at, above or below body temperature.

15 The terms "aliquot," "aliquot of blood" or similar terms used herein include whole blood, separated cellular fractions of the blood including platelets, separated non-cellular fractions of the blood including plasma, plasma components and combinations thereof. Preferably, in human patients, the volume of the aliquot is up to about 400 ml, preferably from about 0.1 to about
20 100 ml, more preferably from about 1 to about 15 ml, even more preferably from about 8 to about 12 ml, and most preferably about 10 ml. When a cellular fraction is used instead of whole blood, the aliquot should contain the number of blood cells which would ordinarily be contained in whole blood of the aforementioned volumes, e.g., 10^3 - 10^{12} . The effect of the combination of
25 stressors is to modify the blood, and/or the cellular or non-cellular fractions thereof, contained in the aliquot. The modified aliquot is then re-introduced into the subject's body by any suitable method, most preferably intramuscular injection, but also including subcutaneous injection, intraperitoneal injection, intra-arterial injection, intravenous injection and oral administration.

The optionally applied temperature stressor either warms the aliquot being treated to a temperature above normal body temperature or cools the aliquot below normal body temperature. The temperature is selected so that the temperature stressor does not cause excessive hemolysis in the blood contained in the aliquot and so that, when the treated aliquot is injected into a subject, the desired effect will be achieved. Preferably, the temperature stressor is applied to that the temperature of all or a part of the aliquot is up to about 55°C, and more preferably in the range of from about -5°C to about 55°C.

In some preferred embodiments of the invention, the temperature of the aliquot is raised above normal body temperature, such that the mean temperature of the aliquot does not exceed a temperature of about 55°C, more preferably from about 40°C to about 50°C, even more preferably from about 40°C to about 44°C, and most preferably about $42.5 \pm 1^\circ\text{C}$.

In other preferred embodiments, the aliquot is cooled below normal body temperature such that the mean temperature of the aliquot is within the range of from about 4°C to about 36.5°C, more preferably from about 10°C to about 30°C, and even more preferably from about 15°C to about 25°C.

The oxidative stressor can be the application to the aliquot of solid, liquid or gaseous oxidizing agents. Chemical oxidants such as hydrogen peroxide can be used. Preferably, it involves exposing the aliquot to a mixture of medical grade oxygen and ozone gas, most preferably by applying to the aliquot medical grade oxygen gas having ozone as a component therein. The ozone content of the gas stream and the flow rate of the gas stream are preferably selected such that the amount of ozone introduced to the blood aliquot, either on its own or in combination with one of the other stressors, does not give rise to excessive levels of cell damage, and so that, when the treated aliquot is injected into a subject, the desired effect will be achieved. Suitably, the gas stream has an ozone content of up to about 300 µg/ml, preferably up to about 100 µg/ml, more preferably about 30 µg/ml, even more preferably up to

about 20 µg/ml, particularly preferably from about 10 µg/ml to about 20 µg/ml, and most preferably about 14.5 ± 1.0 µg/ml. The gas stream is suitably supplied to the aliquot at a rate of up to about 2.0 litres/min, even more preferably up to about 0.33 litres/min, and most preferably about 0.24 ± 0.024 5 litres/min. The lower limit of the flow rate of the gas stream is preferably not lower than 0.01 litres/min, more preferably not lower than 0.1 litres/min, and even more preferably not lower than 0.2 litres/min.

The ultraviolet light, which may also be regarded as a stressor, is suitably applied by irradiating the aliquot under treatment from a source of UV 10 light. Preferred UV sources are UV lamps emitting UV-C band wavelengths, i.e. at wavelengths shorter than about 280 nm. Ultraviolet light corresponding to standard UV-A (wavelengths from about 315 to about 400 nm) and UV-B (wavelengths from about 280 to about 315) sources can also be used. As in the case of the oxidative stressor, the UV dose should be selected, on its own 15 or in combination of the other chosen stressor(s), so that excessive amounts of cell damage do not occur, and so that, when the treated aliquot is injected into a subject, the desired effect will be achieved. For example, an appropriate dosage of such UV light, can be obtained from up to eight lamps arranged to be exposed to the sample container holding the aliquot, operated at an intensity to 20 deliver a total UV light energy at 253.7 nm at the surface of the blood of from about 0,025 to about 10 joules/cm², preferably from about 0.1 to about 3.0 joules/cm². Such a treatment, applied in combination with the oxidative environment stressor, provides a modified blood aliquot which is ready for injection into the subject, to cause enhanced levels of IL-10 to be generated *in* 25 *vivo* in the subject.

It is preferred to subject the aliquot to the oxidative environment stressor, the UV light stressor and the temperature stressor simultaneously, following the subjection of the aliquot to the mechanical stress, e.g. by extraction of the blood from the patient. Thus, the aliquot may be maintained at 30 a predetermined temperature above or below body temperature while the

- 11 -

oxygen/ozone gas mixture is applied thereto and while it is irradiated with ultraviolet light.

The time for which the aliquot is subjected to the stressors is normally within the time range of from about 0.5 minutes up to about 60 minutes. The time depends to some extent upon the chosen combination of stressors. When UV light is used, the intensity of the UV light may affect the preferred time. The chosen temperature level may also affect the preferred time. When oxidative environment in the form of a gaseous mixture of oxygen and ozone applied to the aliquot is chosen as one of the two stressors, the concentration of the oxidizing agent and the rate at which it is supplied to the aliquot may affect the preferred temperature. Some experimentation to establish optimum times may be necessary on the part of the operator, once the other stressor levels have been set. Under most stressor conditions, preferred times will be in the approximate range of from about 2 to about 5 minutes, more preferably about 3 minutes. The starting blood temperature, and the rate at which it can be warmed or cooled to a predetermined temperature, tends to vary from subject to subject. Warming is suitably by use of one or more infrared lamps placed adjacent to the aliquot container. Other methods of warming can also be adopted.

As noted, it is preferred to subject the aliquot of blood to a mechanical stressor, as well as the chosen stressor(s) discussed above. Extraction of the blood aliquot from the patient through an injection needle constitutes the most convenient way of obtaining the aliquot for further extracorporeal treatment, and this extraction procedure imparts a suitable mechanical stress to the blood aliquot. The mechanical stress may be supplemented by subsequent processing, for example the additional mechanical shear stress caused by bubbling as the oxidative stressor is applied.

In the practice of the preferred process of the present invention,

- 12 -

the blood aliquot may be treated with the heat, UV light and oxidative environment stressors using an apparatus of the type described in aforementioned U.S. Patent No. 4,968,483 to Mueller. The aliquot is placed in a suitable, sterile container, which is fitted into the machine. A UV-permeable
5 container is used and the UV lamps are switched on for a fixed period before the other stressor is applied, to allow the output of the UV lamps to stabilize. When a temperature stressor is used in combination, the UV lamps are typically on while the temperature of the aliquot is adjusted to the predetermined value, e.g. $42.5 \pm 1^\circ\text{C}$. Four UV lamps are suitably used, placed around the container.

10 In the administration of the extracorporeally treated aliquot to the patient for the stimulation of IL-10 secretion in the patient's body, a mammalian patient is preferably given one or more courses of treatments, each course of treatment comprising the administration to a mammalian subject of one or more (e.g. one to six) aliquots of mammalian blood modified as discussed above.

15 The pharmaceutical compositions of this invention may optionally include a pharmaceutically acceptable excipient. Some examples of suitable excipients include sterile water, sterile saline, phosphate buffered saline, and the like.

For optimum effectiveness of the treatment, it is preferred that no
20 more than one aliquot of modified blood be administered to the subject per day, in one or more injection sites, and that the maximum rest period between any two consecutive aliquots during the course of treatment be no greater than about 21 days. Booster treatments as described below may advantageously be used. As used herein, the term "rest period" is defined as the number of days
25 between consecutive aliquots or consecutive courses of treatment on which no aliquots of modified blood are administered to the subject.

Therefore, except where aliquots are administered to the subject on consecutive days, a rest period of from 1 to 21 days is provided between any

- 13 -

two aliquots during the course of treatment. Moreover, at least one of the rest periods during the course of treatment preferably has a length of about 3 to 15 days.

Although it may be sufficient to administer only one course of treatment as described above to the subject, it may be preferred in some circumstances to administer more than one course of treatment, or to follow the above-described course of treatment by periodic "booster" treatments, if necessary, to maintain the desired effects of the present invention. For example, it may be preferred to administer booster treatments at intervals of 3 to 4 months following the initial course of treatment, or to administer a second course of treatments to the subject following a rest period of several weeks or months.

The process of the present invention increases the IL-10 level in a mammalian patient's body, both in tissue and in blood, and accordingly shows potential in the treatment and prophylaxis of a wide variety of inflammatory events and other disorders which are associated with IL-10 deficiencies.

The invention is further illustrated and described with reference to the following specific examples, comprising animal studies conducted in an approved manner. The system chosen to demonstrate the role and effect of enhanced secretion of IL-10 in mammalian patients is contact hypersensitivity, a T-cell mediated delayed-type hypersensitivity reaction in which the skin of a patient exhibits a reaction to an agent which the body has previously encountered, by contact or by inoculation. There is available an established experimental mouse model for induction and testing treatments of this disorder, as described in the following Examples. In addition genetically modified laboratory mice, specifically bred to produce no IL-10, are available commercially to permit testing of the effects of various processes on production, see Example 4 below.

Patients having IL-10 deficiency-associated disorders can be identified by an examination of their symptoms. The presence of the visible symptoms of psoriasis or pemphigus on a patient's skin, or the presence of symptoms of inflammatory bowel disease in a patient, are evidence of IL-10 deficiency. Such identification can also be made, or confirmed, by measurement of IL-10 and IL-10 mRNA in affected tissues of the patient, in the patient's blood and/or the patient's blood cells. IL-10 measurements can be conducted by methods well known to those skilled in the art - see for example the aforementioned papers of Biorencino et al. and Kondo et al., page 1 hereof, and especially references cited therein. Commonly, antibody measurements are used, in plasma or tissue, as with measurements of other cytokines.

A patient thus identified as having an IL-10 deficiency-associated disorder may be evaluated to determine whether that disorder can be effectively treated by increasing the amount of *in vivo* IL-10 secretion, by administering IL-10 from an external source and observing the resultant effect on the patient's symptoms of this disorder. IL-10 is commercially available, at least in test quantities. It can be administered to the test patient intravenously or by local injection at the site of the disorder, as a liquid infusion in a biologically acceptable carrier.

20 EXAMPLE 1

The effectiveness of the treatment according to a preferred embodiment of the present invention, on contact hypersensitivity (CHS), was assessed on laboratory mice, according to approved animal experimentation procedures, using the method described by Kondo et al., "Lymphocyte function associated antigen-1 (LFA-1) is required for maximum elicitation of allergic contact dermatitis" Br J. Dermatol. 131:354-359, 1994, with minor variations. The disclosure thereof is incorporated herein by reference. Briefly, to induce CHS, the abdominal skin of each mouse was shaved and painted with dinitrofluorobenzene DNFB, the sensitizing chemical, using 25 µl of 0.5%

- 15 -

DNFB in 4:1 acetone: olive oil solution. This sensitization was applied to four groups of five Balb C mice.

Whole blood was obtained from Balb/c mice, by extraction from a main artery through an injection needle, and treated with an anti-coagulant. An aliquot of this was subjected to the process of a preferred embodiment of the invention, to obtain treated blood. The remainder was left untreated, for use in control experiments. Since these mice are genetically identical, the administration of the treated blood to others of the group is equivalent to administration of the treated blood to the donor animal.

To obtain treated blood, the selected aliquot, in a sterile, UV-transmissive container, was treated simultaneously with a gaseous oxygen/ozone mixture and ultraviolet light at elevated temperature using an apparatus as generally described in aforementioned U.S. Patent No. 4,968,483 Mueller et al. Specifically, 10 ml of citrated blood was transferred to a sterile, low density polyethylene vessel (more specifically, a Vasogen VC7002 Blood Container) for ex vivo treatment with stressors according to the invention. Using an apparatus as described in the aforementioned Mueller patent (more specifically, a Vasogen VC7001 apparatus), the blood was heated to $42.5 \pm 1^\circ\text{C}$ and at that temperature irradiated with UV light principally at a wavelength of 253.7 nm, while oxygen/ozone gas mixture was bubbled through the blood to provide the oxidative environment and to facilitate exposure of the blood to UV. The constitution of the gas mixture was $14.5 \pm 1.0 \mu\text{g}$ ozone/ml, with the remainder of the mixture comprising medical grade oxygen. The gas mixture was bubbled through the aliquot at a rate of $240 \pm 24 \text{ ml/min}$ for a period of 3 minutes.

Of the 4 groups of sensitized mice, the first, control group A-1 received no treatment. The second, control group B-1, was treated with physiological saline, 50 μl . The third, control group C-1, was sham treated, with 50 μl of blood which had been extracted but not treated with the stressors. The

- 16 -

fourth, test group D-1, was treated with 50 µl of blood subjected to stressors as described above. Treatments, each involving intramuscular injection of 50 µl of the respective liquid, started on the day of sensitization, and was repeated every day for a total of 6 days. On the same day as the last treatment, but after
5 its administration, the animals were challenged with DNFB, by applying to the ears of each animal 10 µl of 0.2% solution of DNFB. Inflammation due to CHS manifests itself in a swelling of the ears. Ear thickness was measured, 24 hours after challenge, with a Peacock spring-loaded micrometer (Ozaki Co., Tokyo, Japan). The results were expressed as the change (from pre-challenge
10 level) in ear thickness and represent the mean maximal increase at 24 hours after challenge.

The experiments were repeated two more times, using two more sets of four groups of animals, to ensure statistical significance in the results. Figure 1 of the accompanying drawings is a graphical presentation of these
15 results. A notable and significant reduction in ear thickness (inflammation) is to be observed with the animals treated according to this preferred process of the invention, as compared with any of the other groups. Figure 2 of the accompanying drawings represent photographs of cross-sections of the ears of a representative treated animal of group D-1 (picture (a)) and a representative
20 untreated group A-1 animal (picture (b)). The decreased skin thickness, and the reduced lymphocyte infiltration (lower density of dark stained cells) is readily apparent on picture (a) from the treated animal, further demonstrating a significant reduction in inflammation.

The percentage suppression when compared with the standard
25 CHS response (no treatment, control group A-1) is 8% for the saline treatment group B-1, 14% for the sham treatment group C-1 and 46% for group D-1, treated according to the embodiment of the process of the invention.

EXAMPLE 2

- 17 -

The procedure of Example 1 was followed, using four groups of Balb/c mice, with one group receiving a blood aliquot which had been subjected to UV and ozone/oxygen bubbling, as described, but without application of the heat stressor (i.e. treated at room temperature). Thus, group A-2 received no treatment, group B-2 received untreated blood (sham treatment), group C-2 received blood treated with UV and ozone but no heat, and group D-2 received blood treated the same way as in the case of group D-1 of Example 1.

The results are presented graphically on Fig. 3, in the same manner as

Fig. 1. The result from group D-2 is marginally better than that from group C-2. The percentage suppression when compared to the standard CHS response (no treatment, group A-2) is 9% for group B-2, sham treatment, 52.5% for group C-2 and 54% for group D-2.

EXAMPLE 3

Whole blood was obtained from Balb/c mice. Part of the blood was subjected to UV, ozone and heat treatment as described in Example 1, and part of the blood remained untreated. Both the untreated blood and the treated blood were centrifuged to obtain a cellular fraction, and washed with saline. The treated and untreated fractions were administered to animals challenged with DNFB to develop contact hypersensitivity as described in Example 1.

Four groups of 5 mice each were injected according to the schedule of Example 1, and evaluated, as follows: Group A-3 - no-treatment; Group B-3 - cellular fraction of sham treated blood; Group C-3 - cellular part of treated blood; Group D-3 - whole treated blood. The administrations to the mice took place just prior to sensitization with 0.5% DNFB and continued every day until challenge with 0.2% DNFB, 5 days later. A total of 6 injections were administered to each mouse.

The ear swelling of each mouse was measured 24 hours after challenge. Each experiment was repeated three times, to ensure statistical significance of the results. Net ear swelling as a measure of contact hypersensitivity and suppression thereof was calculated as $1 - (\text{ear swelling of blood administered mouse} / \text{ear swelling of no blood administered mouse}) \times 100$.

The results are presented graphically on Fig. 4, a summary of three experiments. A significant suppression of CHS is seen with the cellular fraction of the treated blood. There was no significant difference between the treated cellular fraction and treated whole blood.

10 EXAMPLE 4

To demonstrate the fundamental role of IL-10 secretion in the processes described above, the procedure of Example 1 was essentially repeated, using a genetic strain of laboratory mice deficient in the gene responsible for IL-10 production and secretion, i.e. IL-10 knock-out mice.

15 These are available from laboratory animal sources, for approval experimental purposes.

Four groups each comprising five IL-10 knock-out mice were sensitized with DNFB, as described in Example 1. Whole blood was obtained from the IL-10 knock-out mice, by extraction from a main artery through an injection needle, and treated with an anti-coagulant. Aliquots of this blood were treated as described in Example 1, and other aliquots left-untreated for use as controls.

Control group A-4 received no injection. The animals of Control group B-4 were treated with physiological saline. The animals of control Group C-4 were then treated with 50 μ l of blood which had been extracted but not treated with stressors. The fourth test group of animals D-4 were treated with 50 μ l of blood subjected to stressors as described. The treatment schedules,

- 19 -

challenge with DNFB and measurement of results via ear swelling were all as described in Example 1.

The results were shown graphically on accompanying Figure 5. There is no difference between any of the four groups. This demonstrates that
5 the treatment according to the invention is ineffective when applied to IL-10 knock-out mice whereas it is very effective when applied to mice of the same genetic background but expressing the IL-10 gene, so that IL-10 secretion is a key function in the treatment.

What is Claimed is:

1. A method for the prophylaxis or therapeutic treatment of an IL-10 deficiency-mediated disease in a mammalian patient, which method comprises:
 - 5 administering to said patient an aliquot of blood which has been treated *ex vivo* with at least one stressor selected from the group consisting of an oxidative environment, thermal stress and UV light,
wherein the concentration of IL-10 secreted by immune cells in the blood or tissues of said patient is increased, with an associated reduction of
10 harmful inflammatory effects of the IL-10 deficiency-mediated disease.
 2. The method of Claim 1, wherein the oxidative environment comprises applying an oxidizing agent to the aliquot.
 3. The method of Claim 2, wherein the oxidative agent comprises ozone gas, and the ozone gas is introduced into the blood aliquot in
15 an amount which does not give rise to excessive levels of cell damage.
 4. The method of Claim 2, wherein the oxidizing agent comprises a mixture of ozone gas and medical grade oxygen, the ozone gas being contained in the mixture in a concentration of up to about 300 µg/ml.
 5. The method of Claim 4, wherein the ozone gas is
20 contained in the mixture in a concentration of up to about 30 µg/ml.
 6. The method of Claim 5, wherein the ozone gas is contained in the mixture in a concentration of from about 13.5 µg/ml to about 15.5µg/ml.
 7. The method of Claim 4, wherein the mixture is applied to
25 the aliquot at a flow rate of up to about 0.33 litres/min.

8. The method of Claim 7, wherein the mixture is applied to the aliquot at a flow rate of from about 0.21 litres/min to about 0.27 litres/min.
9. The method of Claim 1, wherein the electromagnetic emission comprises ultraviolet light having one or more UV-C band
5 wavelengths.
10. The method of Claim 1, wherein the temperature to which the aliquot is cooled or heated is a temperature which does not result in substantial hemolysis of the blood in the aliquot.
11. The method of Claim 1, wherein the temperature stressor
10 is applied so that the temperature of at least part of the aliquot is in the range of from about -5° C to about 55° C.
12. The method of Claim 1, wherein the mean temperature of the blood in the aliquot is in the range of from about 37° C to about 44° C.
13. The method of Claim 1, wherein the mean temperature of
15 the blood in the aliquot is in the range of from about 0° C to about 36.5° C.
14. The method of Claim 1, wherein the mean temperature of the blood in the aliquot is in the range of from about 10° C to about 30° C.
15. The method of Claim 1, wherein the temperature is in the range of from about 37° C to about 55° C.
16. The method of Claim 15, wherein the temperature is 42.5 ±
20 1° C.
17. The method of Claim 1, wherein the volume of the aliquot is up to about 400 ml.

- 22 -

18. The method of Claim 17, wherein the volume of the aliquot is about 10 ml.

19. The method of Claim 17, wherein the volume of the aliquot is about 2 ml.

5 20. The method of Claim 1, wherein the aliquot is subjected to the stressors for a period of up to about 60 minutes.

21. The method of Claim 20, wherein the aliquot is subjected to the stressors for a period of about 3 minutes.

10 22. The method of Claim 1, wherein the blood is administered to the mammal by a method suitable for vaccination selected from the group consisting of intra-arterial injection, intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection, and oral, nasal or rectal administration.

15 23. The method of Claim 1, wherein all of the stressors are simultaneously administered to the aliquot.

24. The method of Claim 1, wherein any two of the stressors are simultaneously administered to the aliquot.

25. The method of Claim 24 wherein the mammal is a human.

20 26. The method of Claim 25 wherein the IL-10 deficiency-mediated disease is pemphigus.

27. The method of Claim 1 including the additional steps of:

(a) identifying a patient having an IL-10 deficiency-mediated disease condition, or is at risk of having an IL-10 deficiency-mediated disease

- 23 -

condition, which has a significant inflammatory component;

(b) evaluating the patient identified in (a) above to determine whether that disease condition or risk of disease condition can be effectively treated by increasing the concentration of IL-10 in the patient; and

5 (c) if an increase in the concentration of IL-10 would be suitable for the prophylactic or therapeutic treatment of such a disease, then administering to said patient an aliquot of blood which has been treated *ex vivo* with at least one stressor selected from the group consisting of an oxidative environment, thermal stress and UV light.

10 28. A method for the prophylactic or therapeutic treatment of inflammatory components and inflammatory aspects of an IL-10 deficiency-mediated disease in a mammalian patient, which method comprises:

(a) identifying a patient having an IL-10 deficiency-mediated disease condition, or is at risk of having an IL-10 deficiency-mediated disease
15 condition, which has a significant inflammatory component;

(b) evaluating the patient identified in (a) above to determine whether that disease condition or risk of disease condition can be effectively treated by increasing the concentration of IL-10 in the patient; and

(c) if an increase in the concentration of IL-10 would be
20 suitable for the prophylactic or therapeutic treatment of such a disease, then administering to said patient an aliquot of blood which has been treated *ex vivo* with at least one stressor selected from the group consisting of an oxidative environment, thermal stress and UV light;

wherein the concentration of IL-10 secreted by immune cells in
25 the blood or tissues of said patient is increased, with an associated reduction of harmful inflammatory effects of the IL-10 deficiency-mediated disease.

29. A method for preventing or treating an IL-10 deficiency-associated disorder in a mammalian patient which method comprises (a) identifying a patient having an IL-10 deficiency-mediated disorder which

- 24 -

disorder is characterized by a decreased amount of IL-10 secretion; (b) evaluating the patient to determine whether that disorder can be effectively treated by increasing the amount of IL-10 secretion; and (c) administering to the patient an effective amount of extracorporeally stressed blood to stimulate IL-10 secretion in the patient.

30. A method for preventing or treating an IL-10 deficiency-mediated disorder in a mammalian patient, which method comprises (a) selecting a patient having an IL-10 deficiency-mediated disorder which disorder is characterized by a decreased amount of IL-10 secretion; (b) evaluating the patient to determine whether that disorder can be effectively treated by stimulating IL-10 secreting cells; and (c) administering to the patient an effective amount of extracorporeally stressed blood to stimulate IL-10 secreting cells thereby increasing the relative proportion of IL-10-secreting cells in the mammalian patient and stimulating the secretion of IL-10.

31. A method for preventing or treating an IL-10 deficiency-mediated disorder in a mammalian patient, which method comprises (a) selecting a patient having an IL-10 deficiency-mediated disorder which disorder is characterized by a decreased amount of IL-10 activity; (b) evaluating the patient to determine whether that disorder can be effectively treated by increasing the activity of IL-10 in the patient; and (c) administering to the patient an effective amount of extracorporeally stressed blood to increase IL-10 activity in the patient.

32. The method according to Claim 29, 30 or 31 wherein the extracorporeally stressed blood is compatible whole blood or blood cells.

33. The process of Claim 32 wherein the extracorporeal stress is an oxidative stress.

- 25 -

34. The process of Claim 32 wherein the extracorporeal stress is UV radiation.

35. The process of Claim 32 wherein the extracorporeal stress comprises simultaneously applying oxidative stress and UV radiation.

5 36. A method for increasing IL-10 levels in the blood and/or tissues of a mammalian patient, which method comprises extracting an aliquot of the patient's blood, extracorporeally applying to at least the cellular portion of the aliquot at least one stressor selected from UV radiation and oxidative stress, and re-administering the resultant aliquot to the mammalian patient.

10 37. The method of Claim 36 wherein both the UV radiation stressor and the oxidative stressor are extracorporeally applied to the aliquot simultaneously.

38. The process of Claim 36 or 37 wherein the oxidative stress is bubbling of a mixture of medical grade oxygen and ozone through the aliquot.

15 39. A pharmaceutical composition for administration to a mammalian patient comprising patient-compatible IL-10 secretion-stimulating mammalian blood cells wherein the blood cells stimulate an increase in IL-10 levels in the blood and/or tissues of the mammalian patient when administered to the mammalian patient.

20 40. The pharmaceutical composition of Claim 39 wherein the blood cells are extracorporeally stressed with at least stressor selected from the group consisting of oxidative stress and ultraviolet radiation stress.

25 41. A process of alleviating the symptoms of, or prophylaxes of, an IL-10 deficiency-associated disorder in mammalian patient, which comprises *in vivo* stimulation of enhanced IL-10 secretions in the mammalian

patient by application to the patient of IL-10 secretions stimulating extracorporeally stressed compatible whole blood or blood cells.

42. A process of alleviating the symptoms of, or prophylaxes of, an IL-10 deficiency-associated disease in a mammalian patient, which
5 comprises *in vivo* increasing the number of relative proportion of IL-10-secreting cells in the mammalian patient and stimulating IL-10 secretion therefrom, by application to the patient of IL-10 cell enhancing extracorporeally stressed compatible whole blood or blood cells.

43. A process of alleviating the symptoms of, or prophylaxes
10 of, an IL-10 deficiency-associated disorder in a mammalian patient, which comprises *in vivo* enhancing the activity of IL-1- in the mammalian patient's body by application to the patient of IL-10 activity increasing extracorporeally stressed compatible whole blood or blood cells.

44. The process of Claim 41, 42 or 43 wherein the
15 extracorporeal stress is an oxidative stress.

45. The process of Claim 41, 42 or 43 wherein the extracorporeal stress is UV radiation.

46. The process of Claim 41, 42 or 43 wherein the extracorporeal stress is a combination of oxidative stress and UV radiation,
20 applied extracorporeally to the whole blood or cellular fraction thereof simultaneously.

47. A process of increasing IL-10 levels in the blood and/or tissues of a mammalian patient, which comprises extracting an aliquot of the patient's blood, extracorporeally applying to at least the cellular portion of the
25 aliquot at least one stressor selected from UV radiation and oxidative stress, and re-administering the resultant aliquot to the mammalian patient.



- 27 -

48. The process of Claim 48 wherein both the UV radiation stressor and the oxidative stressor are extracorporeally applied to the aliquot simultaneously.

49. The process of Claim 47 or Claim 48 wherein the oxidative
5 stress is bubbling of a mixture of medical grade oxygen and ozone through the aliquot.

50. A biologically acceptable composition of matter for
administration to a mammalian patient, said composition of matter comprising
extracorporeally stressed compatible mammalian blood cells which have been
10 subjected to at least one of oxidative stress and ultraviolet radiation stress, said
composition of matter having the ability, upon administration to the mammalian
patient, of stimulating an increase in IL-10 levels in the blood and/or tissues of
the mammalian patient.

1/3

**FIG. 1****FIG. 3**

2/3




FIG. 2

3/3




FIG. 4




FIG. 5

10/030418 -

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 November 2001 (15.11.2001)

PCT

(10) International Publication Number
WO 01/85185 A3

- (51) International Patent Classification⁷: **A61K 35/14**, 41/00, A61P 37/00
- (21) International Application Number: PCT/CA01/00679
- (22) International Filing Date: 11 May 2001 (11.05.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
2,308,105 11 May 2000 (11.05.2000) CA
- (71) Applicant (for all designated States except US): **VASO-GEN IRELAND LIMITED [IE/IE]**; Shannon Airport House, Shannon, Co. Clare (IE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SAUDER, Daniel** [CA/CA]; 90 Munro Boulevard, Toronto, Ontario M2P 1L4 (CA). **MANDEL, Arkady** [CA/CA]; 277 Hidden Trail, North York, Ontario M2R 3S7 (CA). **BOLTON, Anthony, E.** [GB/GB]; Ivy Cottage, Sherwood Road, Tideswell, Derbyshire SK17 8HS (GB).
- (54) Agent: **HIRONS, Robert, G.**; Ridout & Maybee LLP, 150 Metcalfe Street, 19th Floor, Ottawa, Ontario K2P 1P1 (CA).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
- (88) Date of publication of the international search report:
10 May 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/85185 A3

(54) Title: TREATMENT OF IL-10 DEFICIENCIES

(57) Abstract: Mammalian disorders associated with a deficiency in the cytokine interleukin-10 (IL-10) can be alleviated by stimulating *in vivo* secretion and/or activity of IL-10 in the patient's blood or tissues by application of external stimulus.

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 29312-0138	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/CA 01/00679	International filing date (day/month/year) 11/05/2001	(Earliest) Priority Date (day/month/year) 11/05/2000
Applicant VASOGEN IRELAND LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.



as suggested by the applicant.



because the applicant failed to suggest a figure.



because this figure better characterizes the invention.



None of the figures.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K35/14 A61K41/00 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 07436 A (VASOGEN INC.) 26 February 1998 (1998-02-26)	39, 40, 50
Y	page 9, line 15 -page 10, paragraph 2; claims; example 3 page 17, paragraph 4 -page 18, paragraph 1 ---	1-50
Y	P. TOTO ET AL.: "Immune modulation in pemphigus vulgaris: Role of CD28 and IL-10." THE JOURNAL OF IMMUNOLOGY, vol. 164, no. 1, 1 January 2000 (2000-01-01), pages 522-529, XP002187080 BALTIMORE, PA, US cited in the application page 527, right-hand column, last paragraph --- -/--	1-50

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

10 January 2002

Date of mailing of the international search report

04/02/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ryckebosch, A

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	G.M. SHIVJI ET AL.: "EFFECTS OF VAS972 THERAPY ON ALLERGIC CONTACT HYPERSENSITIVITY" JOURNAL OF INVESTIGATIVE DERMATOLOGY, NEW YORK, NY, US, vol. 114, no. 4, April 2000 (2000-04), page 862 XP000960563 ISSN: 0022-202X	39, 40, 50
Y	abstract nr. 675	1-50
A	EP 0 392 429 A (F. HOFFMANN-LA ROCHE AG) 17 October 1990 (1990-10-17) page 3, line 46 -page 4, line 34; claims 1,8-10	1-50
P, X	G.M. SHIVJI ET AL.: "THE EFFECT OF VAS972 ON ALLERGIC CONTACT HYPERSENSITIVITY" JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, DECKER PERIODICALS FOR THE CANADIAN DERMATOLOGY ASSOCIATION,, CA, vol. 4, no. 3, July 2000 (2000-07), pages 132-137, XP000960566 ISSN: 1203-4754	1-25, 27-50
Y	page 135, right-hand column, line 6 -page 136, right-hand column, paragraph 1	26
P, X	WO 00 62788 A (VASOGEN IRELAND LIMITED) 26 October 2000 (2000-10-26) claims 1-12; examples	39, 40, 50

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 01/00679

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9807436	A	26-02-1998	US 5980954 A	09-11-1999
			AU 724265 B2	14-09-2000
			AU 3844297 A	06-03-1998
			WO 9807436 A1	26-02-1998
			EP 0920322 A1	09-06-1999
			JP 2000517302 T	26-12-2000
			US 6204058 B1	20-03-2001
<hr/>				
EP 392429	A	17-10-1990	US 4999375 A	12-03-1991
			AT 87205 T	15-04-1993
			DE 59001061 D1	29-04-1993
			DK 392429 T3	19-04-1993
			EP 0392429 A1	17-10-1990
			JP 2290814 A	30-11-1990
			US 5036102 A	30-07-1991
<hr/>				
WO 0062788	A	26-10-2000	AU 4278200 A	02-11-2000
			WO 0062788 A2	26-10-2000
<hr/>				